NCT03089879View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 16, 2017

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Dysentery, Bacillary
Interventions
BIOLOGICAL

GVGH Shigella sonnei 1790GAHB vaccine

Single dose administered at Day 1, by intramuscular injection.

Trial Locations (1)

75679

GSK Investigational Site, Paris

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03089879 - A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study | Biotech Hunter | Biotech Hunter